Gentronix Limited completed a successful £610k Rights Issue in May 2010, which was principally underwritten by NVM Private Equity Ltd and YFM Private Equity, but positively supported by several existing private shareholders. The company has raised the cash to provide working capital to fund growth in its IP and Service businesses, as it positions itself to become the leading European supplier of genotoxicity assays and services.
For further information regarding the Gentronix Limited investment strategy, please contact John Nicholson, Gentronix CEO, on +44 (0)161 606 7267 or by e-mail at john.nicholson@gentronix.co.uk